Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update. (3rd July 2019)

• Record Type: Journal Article
• Authors: Greco, Antonio; Capranzano, Piera; Barbanti, Marco; Tamburino, Corrado; Capodanno, Davide
• Is Part Of: Expert review of cardiovascular therapy. Volume 17:Number 7(2019)
• Page Start: 479
• Page End: 496
• Publication Date: 2019-07-03
• Subjects: Anticoagulant therapy -- antiplatelet therapy -- antithrombotic therapy -- aortic stenosis -- bleeding -- cardiovascular events -- transcatheter aortic valve implantation; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1080/14779072.2019.1632189
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Introduction : Transcatheter aortic valve implantation (TAVI) is the treatment of choice for a large proportion of patients with severe aortic stenosis. Despite numerous technological and clinical advances, TAVI remains associated with thrombotic complications requiring antithrombotic pharmacotherapy, which exposes to the risk of bleeding, especially in elderly individuals. The optimal antithrombotic regimen following TAVI is uncertain and several investigations are ongoing. Areas covered : Clinical guidelines are mostly driven by observational trials and experts' opinions, thus resulting into low-grade level of evidence. The aim of the current review is to critically explore the epidemiology, pathophysiology and prognostic value of thrombotic and bleeding events after TAVI, and to review the current literature on antithrombotic strategies following the procedure. Expert opinion : Thrombotic and bleeding events remain major complications occurring in the frail population that is currently offered TAVI. Waiting for upcoming evidence from ongoing randomized clinical trials, tailoring antithrombotic therapies based on patients' characteristics, values and circumstances is a preferable approach.